Canadian Cancer Trials Group Bulletins

Disease Site Updates

Canadian Cancer Trials Group MA.32 Accrual Update

Canadian Cancer Trials Group MA.32 -- A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

Accrual to MA.32 has been impressive with 177 patients enrolled in October alone. The Juravinski Cancer Centre at the Hamilton Health Sciences Centre now has the distinction of having enrolled 100 patients - more enrollments than any other MA.32 site. Sincere congratulations and thank you for your impressive support!

As of November 8, 2012, there are over 3000 patients enrolled in MA.32 and the target of 3582 is drawing near. Today, we have posted on the MA.32 trial-specific website (under Accrual Updates) -- -- the first in a series of updates regarding the projected date of trial closure so that all sites will be aware of the time remaining in which to approach patients about participation.

Please continue your tremendous work! Your support for and contributions to this research are very much appreciated.

If you have any questions or need more information, please contact Catherine Elliott, MA.32 Study Coordinator, at 613-533-6430 or